According to the latest report published by Credence Research, Inc. “Global Autoinjectors Market (Manual Injection Autoinjectors, Automated Injection Autoinjectors, Reusable Autoinjectors, Disposable Autoinjectors, Variable Dose Autoinjectors & Smart Autoinjectors; & Therapeutic Areas) – Growth, Future Prospects and Competitive Assessment, 2016 – 2022,” the autoinjectors market was valued at USD 869.0 Mn in 2015, and is expected to reach USD 2,740.7 Mn by 2022, expanding at a CAGR of 18% from 2016 to 2022.
Browse the full report Global Autoinjectors Market – Growth, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at http://www.credenceresearch.com/report/autoinjectors-market
The global autoinjectors market is anticipated to undergo swift progress during the forecast period. This market is characterized by rapid technological developments, growing count of severe allergy patients and growing awareness about self-administered prefilled injections. The demand for disposable autoinjectors will grow significantly during the forecast period.
Due to corresponding demands from drug administration industry, the biopharmaceutical companies worldwide have introduced several solutions for injectable drug delivery and are perpetually pushing for improvements in design and mechanism. It is expected that a significant part of new treatment introductions in the market will comprise of injectables, out of which autoinjectors is the fastest emerging drug delivery solutions, since these products deliver better patient experience and treatment adherence through safe self-administration at home. Apart from the offered patient benefits, reduction in the number of hospital visits can ultimately assist in reducing cost of healthcare and contain the burden on healthcare personnel. New ergonomic designs and mechanisms introduced in autoinjectors have also helped to efficiently address patient dexterity issues and minimize the risk of needle-stick injuries.
Autoinjectors are being increasingly considered by biopharmaceutical companies as an appropriate solution to commercialize their therapeutic solutions. However for successful commercialization and implementation of related strategies, the companies require detailed planning, thorough knowledge of drug-device combination mechanism, regulatory requirements and synergy with device manufacturers. Acting against this, biopharmaceutical companies and device manufacturers have varied product lifecycles and thus product development process may lead to gaps that might be crucial for the overall project and affect commercialization and profitability. It is hence crucial for biopharmaceutical companies to have in-depth understanding of every intermediate stage, the stage of entry of device manufacturer, meeting regulatory mandates and other such processes.
Request Free Sample: http://www.credenceresearch.com/sample-request/58015
This market is intensely competitive, yet a handful of players take over significant market shares. Upcoming introductions of several autoinjector products in 2018 and future will bring significant movements in the overall autoinjectors market. Some of the key players operating in development, manufacture and sale of autoinjectors in the international markets are Biogen Idec, Inc., Becton, Dickinson and Company, Antares Pharma, Inc., Mylan, Inc., Novartis International AG, Unilife Corporation, Pfizer, Inc., Scandinavian Health Ltd., Ypsomed Holding AG, Sanofi S. A., Bayer AG, Emergent BioSolutions and others.
Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
What we do
We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.
No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE,
CA 95103, United States